| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/14/2007 | DE102005059242A1 Molekulare Marker für eine Tumordiagnose und -therapie Molecular markers for tumor diagnosis and therapy |
| 06/14/2007 | DE10053783B4 Verfahren zur Modifizierung von dendritischen Zellen A process for the modification of dendritic cells |
| 06/14/2007 | CA2640836A1 Method for generating dendritic cells employing decreased temperature |
| 06/14/2007 | CA2639074A1 Marked bovine viral diarrhea virus vaccines |
| 06/14/2007 | CA2638902A1 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
| 06/14/2007 | CA2632744A1 Combination therapy and antibody panels |
| 06/14/2007 | CA2632732A1 Method of using il6 antagonists with proteasome inhibitors |
| 06/14/2007 | CA2632516A1 Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants |
| 06/14/2007 | CA2632483A1 Improved influenza vaccine |
| 06/14/2007 | CA2632434A1 Methods and compositions relating to adhesins as adjuvants |
| 06/14/2007 | CA2632419A1 Genetically recombinant anti-perp antibody |
| 06/14/2007 | CA2632417A1 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| 06/14/2007 | CA2632402A1 Treatment of epstein-barr virus-associated diseases |
| 06/14/2007 | CA2631981A1 Methods and compositions for needleless delivery of binding partners |
| 06/14/2007 | CA2631952A1 Methods and compositions for needleless delivery of antibodies |
| 06/14/2007 | CA2631785A1 Methods for generating antigen-specific effector t cells |
| 06/14/2007 | CA2630157A1 Ctla-4 antibody dosage escalation regimens |
| 06/13/2007 | EP1795205A2 Method for accessing microbial diversity |
| 06/13/2007 | EP1795204A1 Functional composition or food containing whey protein, antibody derived from milk, or antibody |
| 06/13/2007 | EP1795203A2 Fhit proteins and nucleic acids and methods based thereon |
| 06/13/2007 | EP1794327A2 Strain independent amplification of pathogens and vaccines thereto |
| 06/13/2007 | EP1794187A1 Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor |
| 06/13/2007 | EP1794186A2 Group a streptococcus crge protein |
| 06/13/2007 | EP1794185A1 Piscirickettsia salmonis antigens and use thereof |
| 06/13/2007 | EP1793858A2 Human monoclonal anti-ctla4 antibodies in cancer treatment |
| 06/13/2007 | EP1793857A2 Combination therapy with anti-ctla4 and anti-4-1bb antibodies |
| 06/13/2007 | EP1793856A2 Methods and compositions for treating allergic inflammation |
| 06/13/2007 | EP1793855A2 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 06/13/2007 | EP1793854A1 Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
| 06/13/2007 | EP1793853A1 Liquid allergy vaccine formulation for oromucosal administration |
| 06/13/2007 | EP1793852A1 Inactivated poliomyelitis vaccine derived from sabin strain of polio virus |
| 06/13/2007 | EP1793851A1 Methods and compositions for treatment of hematologic cancers |
| 06/13/2007 | EP1793849A2 Immunogenic composition for use in vaccination against staphylococcei |
| 06/13/2007 | EP1793848A1 Method for determining dosage for an oral killed vaccine |
| 06/13/2007 | EP1793802A1 Controlled and directed local delivery of anti-inflammatory compositions |
| 06/13/2007 | EP1470146B1 Antibodies against the muc18 antigen |
| 06/13/2007 | EP1357944B1 Perylenequinones for use with immunotherapy agents |
| 06/13/2007 | EP1335926B1 Method of separating extra-chromosomal dna from other cellular components |
| 06/13/2007 | EP1267925B1 Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 06/13/2007 | EP1244690B1 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent |
| 06/13/2007 | EP1235862B1 A major neutralization site of hepatitis e virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralization antibodies |
| 06/13/2007 | EP1230349B1 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 06/13/2007 | EP1230265B1 Ctage gene family |
| 06/13/2007 | EP1140969B1 Connective tissue growth factor fragments and methods and uses thereof |
| 06/13/2007 | EP1069909B1 Conjugate vaccines for the prevention of dental caries |
| 06/13/2007 | EP1037909B1 Postweaning multisystemic wasting syndrome virus from pigs |
| 06/13/2007 | EP1012304B1 Component of bromelain |
| 06/13/2007 | EP0986572B2 Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| 06/13/2007 | EP0862630B1 HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF |
| 06/13/2007 | EP0680512B1 Immunogenic meningococcal lps and outer membrane vesicles and vaccine therefrom |
| 06/13/2007 | CN1981195A Analysis of saccharide vaccines without interference |
| 06/13/2007 | CN1981043A Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine |
| 06/13/2007 | CN1981033A Therapeutic, prophylactic and diagnostic agents for hepatitis b |
| 06/13/2007 | CN1981032A A novel strain of sars-associated coronavirus and use thereof |
| 06/13/2007 | CN1980958A Specific binding members against synaptophysin |
| 06/13/2007 | CN1980952A Multimerised HIV fusion inhibitors |
| 06/13/2007 | CN1980697A Preventing autoimmune disease by using anti-CD20 antibody |
| 06/13/2007 | CN1980696A Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients |
| 06/13/2007 | CN1980695A Antigen delivery vectors and constructs |
| 06/13/2007 | CN1980694A Use of gelsolin to treat infections |
| 06/13/2007 | CN1980693A P. gingivalis vaccine |
| 06/13/2007 | CN1980692A Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 06/13/2007 | CN1980691A MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy |
| 06/13/2007 | CN1980649A Methods and reagents for the treatment of immunoinflammatory disorders |
| 06/13/2007 | CN1980641A Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
| 06/13/2007 | CN1980640A Oligonucleotide-containing microspheres, manufacture and delivery thereof |
| 06/13/2007 | CN1980638A Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| 06/13/2007 | CN1977971A Mutant forms of cholera holotoxin as an adjuvant |
| 06/13/2007 | CN1977970A Method for purifying viral vaccine by mixed bed gel filtration chromatography |
| 06/13/2007 | CN1321182C Full gene cloning of horse infectious anemia virus representating virus strain and its use |
| 06/13/2007 | CN1320924C Self-emulsifying vaccine adjuvant and preparation thereof |
| 06/13/2007 | CN1320923C Cancer vaccine contg. cancer antigen based on tumor suppressor gene WT1 product and cationic liposomes |
| 06/12/2007 | US7230155 Method for identifying an agonist of neuronal calcium sensor-1 (NCS-1), for therapy of CNS disorders |
| 06/12/2007 | US7230087 P. aeruginosa mucoid exopolysaccharide specific binding peptides |
| 06/12/2007 | US7230086 Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices |
| 06/12/2007 | US7230084 Therapeutic using a bispecific antibody |
| 06/12/2007 | US7230083 Genetic engineered vitronectin receptors; restenosis therapy, anticancer agents |
| 06/12/2007 | US7230082 PRO polypeptides; monoclonal/humanized antibodies; fusion proteins |
| 06/12/2007 | US7230081 Interferon gamma conjugates |
| 06/12/2007 | US7230076 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/12/2007 | US7230075 Coccidiosis poultry vaccine |
| 06/12/2007 | US7230073 expressed on the surface of sperm; can be used in contraceptive vaccine formulations; for drug screening; genetic engineering |
| 06/12/2007 | US7229975 DNA immunization against chlamydia infection |
| 06/12/2007 | US7229968 Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| 06/12/2007 | US7229841 Expression vector for use treatment of cancer |
| 06/12/2007 | US7229776 For use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control); implicated in atherosclerosis and its etiology |
| 06/12/2007 | US7229772 Detection of apoptotic products |
| 06/12/2007 | US7229770 YKL-40 as a marker and prognostic indicator for cancers |
| 06/12/2007 | US7229763 Assay system using labeled oligonucleotides |
| 06/12/2007 | US7229649 Method and composition for improving sexual fitness |
| 06/12/2007 | US7229645 Spray freeze-dried compositions |
| 06/12/2007 | US7229628 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 06/12/2007 | US7229627 producing aseptic sporozoite-stage Plasmodium parasites; asceptically rearing Anopheles-species eggs; feeding asceptic blood meal comprising gametocyte-stage Plasmodium parasites to infect; dissecting said mosquitoes to remove and pool sporozoite-containing salivary glands |
| 06/12/2007 | US7229626 Administering Clostridial neurotoxin, wherein the Clostridial neurotoxin is administered to an intracranial site which is associated with the symptom of the neuropsychiatric disorder, thereby alleviating the symptom of the neuropsychiatric disorder |
| 06/12/2007 | US7229625 Retrovirus-like particles made non-infectious by a plurality of mutations |
| 06/12/2007 | US7229624 Ordered molecular presentation of antigens, method of preparation and use |
| 06/12/2007 | US7229623 Her-2/neu fusion proteins |
| 06/12/2007 | US7229622 Synthetic chimeric fimbrin peptides |
| 06/12/2007 | US7229621 Method to enhance the immunogenicity of an antigen |
| 06/12/2007 | US7229620 for radiolabeling proteins, peptides and ligands with therapeutic radioisotopes such that these radiolabeled agents may be administered directly to patients without the need for additional purification; for the treatment of cancer |